Mendell J - Search Results

1

Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first-in-human phase I study.

Gewitz A, Mendell J, Wang Y, Harris C, Olenchock BA, Podgrabinska S, Zheng W, Zhao A, Pan H, Vanhoutte F, Davis JD. Gewitz A, et al. Among authors: mendell j. Clin Transl Sci. 2024 Apr;17(4):e13762. doi: 10.1111/cts.13762. Clin Transl Sci. 2024. PMID: 38591811 Free PMC article. Clinical Trial.

2

Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 Trial.

Wang Y, Nguyen JH, de Ruiter RD, Mendell J, Srinivasan D, Davis JD, Eekhoff EMW. Wang Y, et al. Among authors: mendell j. J Clin Pharmacol. 2024 Feb;64(2):264-274. doi: 10.1002/jcph.2344. Epub 2023 Sep 27. J Clin Pharmacol. 2024. PMID: 37694449 Clinical Trial.

3

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, Srinivasan S, Baker-Smith C, Baum S, Brothers JA, Hartz J, Moriarty PM, Mendell J, Bihorel S, Banerjee P, George RT, Hirshberg B, Pordy R. Wiegman A, et al. Among authors: mendell j. Circulation. 2024 Jan 30;149(5):343-353. doi: 10.1161/CIRCULATIONAHA.123.065529. Epub 2023 Oct 20. Circulation. 2024. PMID: 37860863 Free PMC article.

4

Validity of remote live stream video evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.

P Lowes L, Alfano LN, Iammarino MA, Reash NF, Giblin K, Hu L, Yu L, Wang S, Salazar R, Mendell JR. P Lowes L, et al. Among authors: mendell jr. PLoS One. 2024 May 16;19(5):e0300700. doi: 10.1371/journal.pone.0300700. eCollection 2024. PLoS One. 2024. PMID: 38753764 Free PMC article. Clinical Trial.

5

Biochemical and structural insights into a 5' to 3' RNA ligase reveal a potential role in tRNA ligation.

Hu Y, Lopez VA, Xu H, Pfister JP, Song B, Servage KA, Sakurai M, Jones BT, Mendell JT, Wang T, Wu J, Lambowitz AM, Tomchick DR, Pawłowski K, Tagliabracci VS. Hu Y, et al. Among authors: mendell jt. bioRxiv [Preprint]. 2024 Apr 24:2024.04.24.590974. doi: 10.1101/2024.04.24.590974. bioRxiv. 2024. PMID: 38712170 Free PMC article. Preprint.

6

Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy.

Zaidman CM, Goedeker NL, Aqul AA, Butterfield RJ, Connolly AM, Crystal RG, Godwin KE, Hor KN, Mathews KD, Proud CM, Kula Smyth E, Veerapandiyan A, Watkins PB, Mendell JR. Zaidman CM, et al. Among authors: mendell jr. J Neuromuscul Dis. 2024;11(3):687-699. doi: 10.3233/JND-230185. J Neuromuscul Dis. 2024. PMID: 38607761 Free PMC article.

7

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.

Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: mendell jt. Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2. Nat Commun. 2024. PMID: 38480701 Free PMC article.

8

Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74.

Potter RA, Peterson EL, Griffin D, Cooper Olson G, Lewis S, Cochran K, Mendell JR, Rodino-Klapac LR. Potter RA, et al. Among authors: mendell jr. Mol Ther Methods Clin Dev. 2024 Jan 23;32(1):101195. doi: 10.1016/j.omtm.2024.101195. eCollection 2024 Mar 14. Mol Ther Methods Clin Dev. 2024. PMID: 38327805 Free PMC article.

9

Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy.

Mendell JR, Proud C, Zaidman CM, Mason S, Darton E, Wang S, Wandel C, Murphy AP, Mercuri E, Muntoni F, McDonald CM. Mendell JR, et al. Pediatr Neurol. 2024 Apr;153:11-18. doi: 10.1016/j.pediatrneurol.2024.01.003. Epub 2024 Jan 5. Pediatr Neurol. 2024. PMID: 38306745 Free article.

10

Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma.

Hu L, Zhang Y, Guo L, Zhong H, Xie L, Zhou J, Liao C, Yao H, Fang J, Liu H, Zhang C, Zhang H, Zhu X, Luo M, von Kriegsheim A, Li B, Luo W, Zhang X, Chen X, Mendell JT, Xu L, Kapur P, Baldwin AS, Brugarolas J, Zhang Q. Hu L, et al. Among authors: mendell jt. Mol Cell. 2024 Feb 15;84(4):776-790.e5. doi: 10.1016/j.molcel.2023.12.010. Epub 2024 Jan 10. Mol Cell. 2024. PMID: 38211588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

557 results

Search Page